Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Subcutaneous panniculitis-like T-cell lymphoma 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Metformin 16Cyclophosphamide 15Drug Therapy 14Dexamethasone 14Cisplatin 14Cytarabine 11Gemcitabine 10Radiotherapy 9Carboplatin 9Vincristine 8Paclitaxel 8Oxaliplatin 8Idarubicin 8Etoposide 8Docetaxel 8ulipristal acetate 7icotinib 7Sodium Chloride 7Methotrexate 7Fluorouracil 7Dexmedetomidine 7entecavir 6Thalidomide 6Surgical Procedures, Operative 6Sorafenib 6Pemetrexed 6Leuprolide 6Granulocyte Colony-Stimulating Factor 6Epirubicin 6Doxorubicin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Unknown × prednylidene × Clear all
NCT01746992 2017-11-14

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

Ruijin Hospital

Phase 4 Unknown
200 enrolled
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡